Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Sonnet - The Untold Story

Hyperliquid Strategies Q3 Earnings Call Highlights

Hyperliquid Strategies (NASDAQ:PURR) reported a profitable fiscal third quarter, with results driven primarily by appreciation in the HYPE token and continued staking revenue, executives said on the company’s third-quarter 2026 earnings call. CEO David Schamis said the company remains “by far the l

MarketBeat

Claude Opus 4.5 launches: A major upgrade for coding and workplace efficiency

Claude Opus 4.5 has arrived, and it brings with it major improvements to coding and work-based challenges.

Tom’s Guide

This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

Sonnet Bio is pivoting towards becoming a crypto treasury company by accumulating the HYPE Crypto.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

“Creamy fat tones and complex sound architecture”: Magneto takes its Sonnet six-string to new heights and launches its first-ever bass

The one-two release is set to be rolled out in May, with its upgraded Strat-a-like and short-scale bass set to be showcased at NAMM 2025

Guitar World

Thunderbolt 5 dock comes with built-in PCIe 4.0 SSD and four TB5 ports — pricing starts at $399

Sonnet will be the first to ship a Thunderbolt 5 dock with a built-in PCIe 4.0 SSD, which delivers 6,100 MB/s transfers and offers many connectivity options.

Tom’s Hardware

EXCLUSIVE: 'Before IPL, I was not aware I could bowl so quick' - Mayank Yadav

Latest pace Sensation Mayank Yadav Speaks To TOI About India Call-Up, Injury Which Is Common Among Javelin Throwers And How Sonnet Club Took Care Of All Of His Needs…

The Times of India

Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate

The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ:SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) technology. Sonnet will initiate its First-in-Human Phase 1 trial in adult oncology patients in Q2 of 2022. The study will establish…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.